| abstract |
The present invention relates to azetidine and cyclobutane derivatives, as well as their compositions, methods of use, and processes for their preparation, which are useful JAK inhibitors in the treatment of diseases associated with JAK including, for example, inflammatory disorders and autoimmune, as well as cancer. 1. A compound of formula I: or a pharmaceutically acceptable salt thereof, CHARACTERIZED because: L is SO2 or CO; R 1 is C 1-6 C 3-7 cycloalkyl, phenyl, 5- or 6-membered heteroaryl, indolyl, NR 2 R 3, or OR 4; wherein said alkyl, cycloalkyl, phenyl or heteroaryl is optionally substituted with 1-2, or 3 substituents independently selected from F, CN, and C1-4 alkyl; and R2 and R3 are independently selected from H, C1-4 alkyl, and phenyl; and R4 is C1-6 alkyl, phenyl, or benzyl; and because when L is SO2, R1 is different from OR4. |